The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | BREAKWATER Cohort 3: encorafenib, cetuximab & FOLFIRI in BRAF V600E-m mCRC
Scott Kopetz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents progression-free and overall survival analyses from BREAKWATER Cohort 3 (NCT04607421) of first-line encorafenib plus cetuximab combined with FOLFIRI in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). Results demonstrated clinically meaningful and statistically significant improvements in progression-free survival and overall response rate versus control, with a manageable safety profile, supporting this regimen as a practice-changing standard-of-care option in this population. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
